Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label ixekizumab in Japanese patients with moderate-to-severe psoriasis
jRCT2080221846Phase 4
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ixekizumab in psoriasis, sponsored by Eli Lilly and Company.
02
Drugs
ixekizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on jRCT2080221846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221846.